ZCP
CRSP icon

Z3 Capital Partners’s CRISPR Therapeutics CRSP Stock Holding History

Z3 Capital Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$436K Buy
8,000
+1,750
+28% +$92.2K 0.09% 126
2026
Q1 		$297K Buy
6,250
+1,000
+19% +$52.7K 0.08% 145
2025
Q4 		$275K Buy
+5,250
New +$314K 0.07% 156

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Z3 Capital Partners's CRSP Position: Q2 2026 in Review

Z3 Capital Partners increased its CRISPR Therapeutics (CRSP) stake by 28% in Q2 2026, buying an estimated $92.2K and bringing the position to 8,000 shares worth $436K. The position accounts for 0.09% of the portfolio, ranked #126.

Z3 Capital Partners first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. 490 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Z3 Capital Partners held 8,000 shares of CRISPR Therapeutics worth $436K as of Q2 2026.
  • Z3 Capital Partners bought 1,750 CRISPR Therapeutics shares in Q2 2026, an estimated $92.2K.
  • CRISPR Therapeutics made up 0.09% of Z3 Capital Partners's portfolio in Q2 2026, its #126 holding.
  • Z3 Capital Partners first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Z3 Capital Partners's 13F filing for Q2 2026, filed 28 Jul 2026.